Episodit
-
Mind Medicine Australia exists to help alleviate the suffering and suicides caused by mental illness in Australia through expanding the treatment options available to medical practitioners and their patients. We will establish safe and effective psychedelic-assisted treatments to treat a range of mental illnesses.
In furtherance of this mission, The Mind Medicine Australia Podcast ‘Season 2’ aims to connect, listen and share the power of lived experience stories of mental health challenges and altered states that cultivate wellbeing and utilise the collective voices to inform research directions, policy and system change. This podcast will explore modalities including but not limited to altered states from the use of psychedelics, breath work, yoga, mindfulness, meditation, nutrition, sleep and exercise.
--
Tommy Moore is a qualified Nutritionist and Exercise Scientist, studying a Master's degree in Neuroscience (MNSc), and teaching at a Bioscience Education Centre. He also leads specialist educational programs that involve medical, health and biotechnologies to school students (ages 11-18), in the context of sport and human performance.
Tommy was the previous host of the Mind Medicine Australia podcast,
Dr Deb Roberts, PhD is the Mind Medicine Australia Podcast host for Season 2 and has been a MMA volunteer, guides the weekly staff meditation, on the MMA Lived Experience Panel and has a life-long relationship with mental (ill) health yet been able to navigate a fulfilling existence through various means.
She is deeply passionate about conversations related to wellbeing. She uses her own lived experience as well as the reality of having two family members who ended their life seeing no treatment pathway forward. One was her older sister who tried countless medicine combinations, therapies and facilities over 30 years.
Deb’s public health and academic professional background combined with executive roles in the private health care sector have enabled her to understand many facets of the service delivery system.
--
Thank you for listening to the Mind Medicine Australia Podcast. If what you’ve heard in this episode resonates with you, you can offer your support through zero cost means by jumping on to our website and sharing the site to your networks.
You can join our local chapter groups. You can also subscribe to the podcast and follow us and if you feel moved, you can give us a 5 star review.
You can also support Mind Medicine’s work by making a tax deductible donation to us and more specifically you can support the Patient Support Fund. Your donation will support research, access and affordability for psychedelic medicine.
The information provided in this podcast is for general information purposes only and does not constitute the practice of medicine or other professional health care services including the giving of medical advice.
The content of this podcast is not intended to be a substitute for professional and medical recommendation, diagnosis or treatment. The use of information in this podcast is at one’s own discretion and is not an endorsement of use given the complexity inherent in this medicine under the current viable widespread illegality of their usage.
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
This podcast discusses the current state of research on the use of psychedelics in psychiatry, especially psilocybin, for the treatment of depression and other mental illnesses, including the precautions that must be taken before treatment, the standardized four-stage treatment model for depression, and the obstacles that must be overcome to use psychedelic therapy on a larger scale.
Current Status of Psychedelics in Psychiatry (D Nutt & R Cahart-Harris)
Support the podcast
Certificate in Psychedelic Assisted Therapies
Donate to Mind Medicine Australia
In this episode:
The podcast reviews the clinical research on the use of psychedelics in psychiatry, including the history of psychedelic research, recent developments, and the potential of psilocybin as a treatment for various mental illnesses.Psilocybin may be useful in treating depression and has been shown to have antidepressant effects on people with resistant depression, anxiety, and depression symptoms caused by life-threatening cancer diagnoses, as well as in treating alcohol and tobacco dependence.Certain precautions must be taken before treatment, such as assessing whether the patient is suitable for psychedelic therapy and stopping medications that block or attenuate the effects of the psychedelic.Psychedelic therapy involves a standardized four-stage process for depression treatment, which includes assessment, preparation, experience, and integration.One of the main obstacles to using psychedelic therapy on a larger scale is the current resource-intensive model, which requires high-quality training and practice.Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
Puuttuva jakso?
-
In this podcast, we will provide a brief overview of psychedelic-assisted therapy, including its therapeutic process and the psychedelic experience.
Support the podcast
Certificate in Psychedelic Assisted Therapies
Donate to Mind Medicine Australia
In this episode:
The definition of psychedelic-assisted therapyThe three phases of the therapeutic processThe importance of non-psychedelic elements in the therapySet and setting during the psychedelic experienceThe effects of psychedelic compounds on brain activity and subjective experience (aka phenomenology)The need for further research in the field of psychedelic-assisted therapySupport this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
In this podcast, we discuss what the next steps are, following the TGA's decision to change the classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists.
Support the podcast
In this episode:
The mission of Mind Medicine in light of the rescheduling of psilocybin and MDMA for medical use in Australia effective July 1st, 2023.The podcast will shift focus towards a more in-depth analysis of newly published research articles on psychedelics, as well as previous researchMind Medicine Australia is a non-profit organization dedicated to increasing medical access and awareness of psychedelic-assisted therapies.Psychedelics are chemical compounds that temporarily alter brain function resulting in an "altered state of consciousness."Mind Medicine Australia aims to provide better treatment options for patients suffering from mental illness, with a focus on developing clinical implementation frameworks and therapist training protocols.Starting July 1, 2023, authorized prescribers will be able to prescribe psilocybin and MDMA for patients with treatment-resistant depression and post-traumatic stress disorder.Mind Medicine Australia is arranging for these medicines to be supplied through licensed pharmacists holding Schedule 8 permits.Only specialized psychiatrists who meet certain qualifications will be able to prescribe psilocybin and MDMA.Australia is the first nation in the world to reschedule these medicines for medical purposes.Mind Medicine Australia has trained 240 medical professionals through its Certificate in Psychedelic-Assisted Therapies (CPAT) since 2021, and will shortly be launching dates for 2023 intakes.Certificate in Psychedelic Assisted Therapies
Patient Support Fund (Donate)
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
Professor David Nutt is an English neuropsychopharmacologist specialising in the research of drugs that affect the brain.
In this episode:
The Endocannabinoid SystemTHC, CBD and other cannabinoidsCB1 and CB2 receptorsThe Entourage EffectConstituents of cannabisMedicinal CannabisSupport the podcast:
Support the podcast
Support Mind Medicine Australia's mission:
Mind Medicine Australia
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
Dr James Fadiman is an American psychologist and writer.
Fadiman received a Master's degree and a doctorate in Psychology from Stanford University back in 1960. His friend and former Harvard undergraduate advisor, Ram Dass (then known as Richard Alpert), introduced him to psychedelics. Fast-forward 60 years and Fadiman is now known and acknowledged for his research and clinical work in psychedelic therapy and microdosing.
In this episode:
Microdosing: Practice & BenefitsPsychedelics in psychiatryPsychedelics in optimisationHow psychedelics open up the capacity for changeSelf & SelvesSupport the podcast:
Support the podcast
Support Mind Medicine Australia's mission:
Mind Medicine Australia
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
Katrin Preller received her PhD in Psychology and Neuroscience from University of Zurich, Switzerland in 2013. After completing her PhD, she investigated the effects of psychedelics on self-perception and social cognition. Her research interests are centred around the neuropharmacology of emotional and cognitive processes in health and psychiatric illnesses, as well as (pharmacological) neuroimaging analysis methodology. She is particularly interred in substance use disorders as well as the role of the serotonin system in emotion and cognition. She uses psilocybin and LSD to elucidate the role of 5-HT2A/1A receptor functions in human cognition.
In this episode:
Ingestion, absorption, and receptor activation of psilocybin and LSDBrain-wide changesWhy understanding mechanism will help therapy outcomesImplications for psychedelic therapySupport this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
Professor Karl Friston is a British theoretical neuroscientist at University College London and an authority on brain imaging.
Karl has been awarded with countless different prizes and accomplishments, and is considered one of the most influential neuroscientists of the modern era. He invented statistical parametric mapping (SPM), voxel-based morphometry (VBM) and dynamic causal modelling (DCM). Friston currently works on models of functional integration in the human brain and the principles that underlie neuronal interactions. His main contribution to theoretical neurobiology is a free-energy principle for action and perception (active inference).
In this episode:
Functional segregation, integration, and connectivityThe brain's generative modelThe brain's predictive model, prediction error and how to correct prediction errorFree energy principle and active inferencePsychopathology (false inference)How psychedelics alter the hierarchical architecture of the brainSerotonin, interoception, and 5HT2a agonismBrain-mind theoriesSelf-awareness in understanding mindSupport the podcast:
Support the podcast
Support Mind Medicine Australia's mission:
Mind Medicine Australia
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
Dan Engle, MD, is a psychiatrist with a clinical practice that combines aspects of regenerative medicine, psychedelic research, integrative spirituality, and peak performance.
Dan obtained his medical degree from the University of Texas at San Antonio. His psychiatry residency degree is from the University of Colorado Denver, and his child and adolescent psychiatry fellowship degree is from Oregon Health & Science University.
Dr. Engle is an international consultant to several global healing centers facilitating the use of long-standing indigenous plant medicines for healing and awakening. He is the Founder and Medical Director of Kuya Institute for Transformational Medicine in Austin, Texas; Full Spectrum Medicine, a psychedelic integration and educational platform; and Thank You Life, a non-profit funding stream supporting access to psychedelic therapies.
Dr. Engle is the author of The Concussion Repair Manual: A Practical Guide to Recovering from Traumatic Brain Injuries, as well as his more recent new book, A Dose of Hope: A Story of MDMA-Assisted Psychotherapy.
In this episode:
Transformational Medicine - 'hardware and software'A Dose Of HopeThe Power Of StorytellingSelf-Compassion, Self-Worth, and Self-ValueTrauma - Implications, Expressions, and SubjectivityTruths - Objective and SubjectiveMDMA - Psychology and BiologyActivating Your Innate Inner Healing IntelligenceThe Future of Psychiatric CareLinks:
A Dose Of Hope
Dr Dan Engle's Website
Full Spectrum Medicine
Kuya Institute for Transformational Medicine
Thank You Life
Support the podcast:
Support the podcast (Patreon)
Support Mind Medicine Australia's mission:
Mind Medicine Australia
Donate to Mind Medicine Australia
Join a local chapter
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
Lynn-Marie Morski, MD, JD is the president of the Psychedelic Medicine Association, host of the Plant Medicine Podcast, founder of Plant Medicine.org, and the medical director for Way of Leaf.com.
Lynn-Marie is a Mayo Clinic-trained physician in family medicine and sports medicine, as well as an attorney and former adjunct law professor.
She started the Plant Medicine Podcast to bring scientific researchers, practitioners, and those who have been personally affected by the healing powers of these plants together to help educate the public on what is possible and help further research and decriminalization of these substances. She later founded The Psychedelic Medicine Association; a society of physicians, therapists, and health care professionals looking to advance their education on the therapeutic uses of psychedelic medicines.
The Psychedelic Medicine Association (PMA) is a public benefit corporation of healthcare providers aimed at bridging the gap between the advances taking place in the psychedelic research world and medical practitioners.
In this episode:
Factors that influence which psychedelic medicine is best suited for the patientLynn-marie’s therapeutic realisation Fundamentals of Psychedelic MedicineCommon myths or confusions in psychedelic medicineCurrent accessibility Western and indigenous perspectives of illness and wellness4 big hurdles preventing doctors prescribing psychedelicsHow to approach stigma within the health-care communityHarm reductionLinks:
Psychedelic Medicine Association
Plant Medicine Podcast (Spotify)
PlantMedicine.org
Support the podcast:
Support the podcast (Patreon)
Support Mind Medicine Australia's mission:
Mind Medicine Australia
Donate to Mind Medicine Australia
Join a local chapter
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
Adam Gazzaley MD, PhD is a neuroscientist, neurologist, inventor, author, photographer, entrepreneur and investor.
Adam obtained an M.D. and a Ph.D. in Neuroscience at the Mount Sinai School of Medicine in New York, completed Neurology residency at the University of Pennsylvania, and postdoctoral training in cognitive neuroscience at University of California, Berkeley. He is now the David Dolby Distinguished Professor in Neurology, Physiology and Psychiatry at University of California, San Francisco and the Founder / Executive Director of Neuroscape, a translational neuroscience center engaged in technology creation and scientific research.
In this episode:
Humans as information seeking creaturesHow technology has challenged our brainBottom-up and top-down attentionAdvancing psychedelic researchThe role of context in experience outcomesThe mind as a functional product of the brainNeuroplasticity (experience-dependent plasticity and self-directed plasticity)Creating an interpretable real-time experience landscapePsychedelics in neurodegenerative illnessLinks:
Neuroscape
Adam Gazzaley
Support the podcast:
Support the podcast (Patreon)
Support the mission:
Mind Medicine Australia
Donate to Mind Medicine Australia
Join a local chapter
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
Prof David Nutt is Neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep.
David is the chairman of Drug Science, a non-profit which he founded in 2010 to provide independent, evidence-based information on drugs. Nutt is the deputy head of the Centre for Psychedelic Research at Imperial College London. He and his team have published research into psilocybin for TRD, as well as neuroimaging studies investigating psilocybin, MDMA, LSD, and DMT.
In this episode:
How drugs help our understanding of the brainImpact of prohibition on investigation and researchKey terms - decriminalisation, depenalisation, legalisationDrug harm profiles - alcohol, lsd, mdma, psilocybinPhysiology and psychology of addictionBrain-mind interplayThe psychedelic experience and its phenomena The default mode networkFunctional connectivityNeuroplasticityWhy profound alterations in consciousness permit long-term changesSerotonin's role in depressionPsilocybin vs SSRIs and the 5HT2a receptorPsychedelics vs Psychedelic-assisted psychotherapiesLinks:
Drug Science
The Drug Science Podcast
David Nutt on Twitter
Recent paper exploring Psilocybin vs SSRIs:
Serotonin and brain function: a tale of two receptors
Support the podcast:
Support the podcast (Patreon)
Support the mission:
Mind Medicine Australia
Donate to Mind Medicine Australia
Join a local chapter
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
Dennis McKenna is an Ethnopharmacolgist, research pharmacist, lecturer, and author.
Dennis is a founding member and director of ethnographic research at the Heffter Research Institute, a non-profit organization involved in investigating the potential of therapeutic use of drugs. He is the brother of the famous psychedelic advocate Terence McKenna.
In this episode:
Preserving indigenous practice, challenges we faceMckenna Academy of Natural PhilosophyThe brain as a reducing valve of realityThe mind-brain problemPsychedelics bring the background forwardSerotoninConsciousness and symbiosisWhat research questions should be asked in the next 5-10 yearsWho will be the gatekeepers of these medicinesThe need to arm psychiatrists and mental health practitioners with psychedelicsSupport the podcast:
Support the podcast (Patreon)
Support the mission:
Mind Medicine Australia
Donate to Mind Medicine Australia
Join a local chapter
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
Andrew Robb was Australia’s Minister for Trade, Investment, and Tourism.
Currently, Andrew is the chairman of The Robb Group (corporate and investment advisory company) and is a board member for multiple organizations, including Mind Medicine Australia. He is the author of Black Dog Daze: Public Life, Private Demons, his memoir that explores the challenges of managing depression, political ambition, and the life of the liberal party.
In this episode:
Personal journey - political ambition, battles with depressionExperience with antidepressantsWhen his antidepressants stopped workingPsychedelic therapy remission statisticsApproving this type of therapy on the state and federal levelInforming and educating politiciansSupport the podcast:
Support the podcast (Patreon)
Support the mission:
Mind Medicine Australia
Donate to Mind Medicine Australia
Join a local chapter
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
Nigel Denning is the Director and Counselling Psychologist at Integrative Psychology
Nigel is a former Family Violence Co-ordinator for Relationships Australia and is the Deputy President of the In Good Faith Foundation. He has studied in the United States and Europe with Dr. Stanislac Grof, one of the founders of Transpersonal Psychology and Holotropic Breathwork. He has also helped build and deliver the Certificate in Psychedelic-Assisted Therapies (CPAT), which has been developed primarily to meet the demand for trained therapists to provide regulatory approved and research-backed psychedelic-assisted therapies for the treatment.
In this episode:
Consciousness as a discussion in psychologyBio-psycho-social modelPsychedelic-assisted psychotherapyConnectionSelf-transcendenceLoveMeditationCPAT (Certificate in Psychedelic-Assisted Therapies)Links:
CPAT
Integrative Psychology
Support the podcast:
Support the podcast (Patreon)
Support the mission:
Mind Medicine Australia
Donate to Mind Medicine Australia
Join a local chapter
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
Lars Wilde is the President, Chief Business Officer, and Co-founder of COMPASS Pathways.
COMPASS is a UK life sciences company that works to expedite the approval and delivery of mental health therapies to patients and focuses primarily on testing psilocybin for use in patients with treatment-resistant depression (TRD). They have 22 trials running through the US and Europe for TRD.
In this episode:
Personal journey and battles with anxiety, and seeking psychiatric helpThe subjective experience of psilocybin and impact of emotional processing and cognitive functionBirth of COMPASSThe current landscape of the researchModels for therapies and how they can scaleResearch questions that need to be addressedCOMPASS decision to patent psilocybin (and what this means for its scientific exploration)Rescheduling psilocybinLinks:
COMPASS Pathways
Support the podcast:
Support the podcast (Patreon)
Support the mission:
Mind Medicine Australia
Donate to Mind Medicine Australia
Join a local chapter
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
David Bryce Yaden, Ph.D. is a Postdoctoral Research Fellow at Johns Hopkins Medicine in The Center for Psychedelic and Consciousness Research.
David's research focus is on the psychology, cognitive neuroscience, and psychopharmacology of spiritual, self-transcendent, and positively transformative experiences triggered with psychedelic substances and other means. Specifically, he is interested in understanding how these experiences can result in long-term changes to well-being and how they temporarily alter fundamental faculties of consciousness such as the sense of time, space, and self.
He is the editor of Rituals and Practices in World Religions: Cross-Cultural Scholarship to Inform Research and Clinical Contexts. He is currently writing a book called The Varieties of Spiritual Experiences: A Twenty-First Century Update for Oxford University Press. His scientific and scholarly work has been covered by The New York Times, The Wall Street Journal, The Washington Post, New York Magazine, and NPR.
In this episode:
Self-transcendent experience that lead him to this spaceAttempting to understand the brain and mind in these experiencesLeveraging neuroimaging to describe self-transcendence Cautioning neuroimaging to define the psychedelic experienceProspection and the idea of being pulled into the futureSelflessness vs. feelings of connectionTime, space, and selfPsychedelic research entering maturityThe need to arm psychiatrists with psilocybinLinks:
David B. Yaden on Twitter
Psychedelics in Psychiatry - Keeping the Renaissance From Going Off the Rails
Support the podcast:
Support the podcast (Patreon)
Support the mission:
Mind Medicine Australia
Donate to Mind Medicine Australia
Join a local chapter
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
Dr. Rachel Yehuda, PhD. is a Professor of Psychiatry and Neuroscience, and Director of the Center for Psychedelic Psychotherapy and Trauma Research at Mount Sinai School of Medicine in New York.
This research includes the PTSD clinical research program and the Neurochemistry and Neuroendocrinology laboratory at the James J. Peters Veterans Affairs Medical Centre.
In this episode:
Defining traumaDiagnosing post-traumatic stress disorder (PTSD)Symptomatology associated with trauma and PTSDThe stress response, including brain regions associated with memoryCurrent treatments Psychedelic-assisted therapies, including MDMA-assisted psychotherapySupport the podcast:
Support the podcast (Patreon)
Support the mission:
Mind Medicine Australia
Donate to Mind Medicine Australia
Join a local chapter
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
The scope of psychedelic research is expanding and it's only in the last couple of decades that we have been able to find how MDMA, among other psychedelic compounds, exert their effect in the body. Pharmacology is the use, effects, and modes of drug action.
In this episode:
Pharmacology and therapeutic mechanisms of MDMA:Where does psilocybin exert its effect in our body?How is it metabolised?What receptors in the brain and body does it engage with?What is the result of the change in physiology?Support the podcast:
Support the podcast (Patreon)
Support the mission:
Mind Medicine Australia
Donate to Mind Medicine Australia
Join a local chapter
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
-
The scope of psychedelic research is expanding and it's only in the last couple of decades that we have been able to find how psilocybin, as well as other psychedelic compounds, exert their effect in the body. Pharmacology is the use, effects, and modes of drug action.
In this episode:
Pharmacology and therapeutic mechanisms of Psilocybin:Where does psilocybin exert its effect in our body?How is it metabolised?What receptors in the brain and body does it engage with?What is the result of the change in physiology?Support the podcast:
Support the podcast (Patreon)
Support the mission:
Mind Medicine Australia
Donate to Mind Medicine Australia
Join a local chapter
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
- Näytä enemmän
